AR065921A1 - Anticuerpos anti-ige - Google Patents
Anticuerpos anti-igeInfo
- Publication number
- AR065921A1 AR065921A1 ARP080101376A ARP080101376A AR065921A1 AR 065921 A1 AR065921 A1 AR 065921A1 AR P080101376 A ARP080101376 A AR P080101376A AR P080101376 A ARP080101376 A AR P080101376A AR 065921 A1 AR065921 A1 AR 065921A1
- Authority
- AR
- Argentina
- Prior art keywords
- ige
- human
- less measured
- rbl
- recombined
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 abstract 2
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 230000002730 additional effect Effects 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 210000003651 basophil Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000159 protein binding assay Methods 0.000 abstract 1
- 102220286033 rs1553301271 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Composiciones farmacéuticas y métodos para el tratamiento del asma, en particular asma alérgica, así como otros trastornos donde interviene la IgE que incluyen rinitis alérgica y alergias alimentarias. Reivindicacion 1: Un anticuerpo monoclonalhumano, o una porcion de éste de union al antígeno dirigido contra la IgE humana, o una porcion de éste de union al antígeno, caracterizado porque tiene al menos una propiedad adicional seleccionada del grupo que consiste en: a) tiene un valor deCI50 de 0,5 mg/ml o menor medido por su capacidad para reducir el ensayo de union a la célula IgE utilizando una línea celular RBL-2H3 transfectada con el Fc?R1 humano; b) tiene un valor de CI50 de 0,5 mg/ml o menor medido por su capacidad parainhibir la desgranulacion en donde interviene la IgE utilizando una línea celular RBL-2H3 transfectada con el Fc?R1 humano, c) no se entrecruza con la IgE unida al receptor y no estimula la desgranulacion en que interviene la IgE de las células RBL-2H3 (Fc?R1) cultivadas con la IgE humana; d) no se entrecruza con la IgE unida al receptor y no estimula la desgranulacion en que interviene la IgE de basofilos de sangre humana; e) son muy selectivos para la IgE sobre IgA, IgG1 y IgG3 humanas, f)se une a la longitud total de IgE humana con una constante de afinidad, KD, de 15 nM o menor medida por resonancia de plasmon superficial; g) tiene una disociacion (kOff) para la IgE humana de 2 x 10-4 s-1 o menor medida por resonancia de plasmonsuperficial; h) se une al mismo epítopo de la IgE humana como un anticuerpo seleccionado del grupo que consiste en 5.396.1 recombinado; 5.396.1 Hc-S103N Lc-K61R; 6.605.1 recombinado; 6.605.1 (H3Q, M13K, D82E-T25A, T53S); 5.948.1. recombinado, y5.948.1 H100Y.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92154607P | 2007-04-02 | 2007-04-02 | |
| US875507P | 2007-12-20 | 2007-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065921A1 true AR065921A1 (es) | 2009-07-08 |
Family
ID=39831518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101376A AR065921A1 (es) | 2007-04-02 | 2008-04-01 | Anticuerpos anti-ige |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7867494B2 (es) |
| EP (1) | EP2142214A4 (es) |
| JP (1) | JP2010532158A (es) |
| KR (1) | KR20100018499A (es) |
| CN (1) | CN101808661A (es) |
| AR (1) | AR065921A1 (es) |
| AU (1) | AU2008236765A1 (es) |
| BR (1) | BRPI0809677A2 (es) |
| CA (1) | CA2682927A1 (es) |
| CL (1) | CL2008000935A1 (es) |
| DO (1) | DOP2008000018A (es) |
| GT (1) | GT200800034A (es) |
| IL (1) | IL201156A0 (es) |
| MX (1) | MX2009010765A (es) |
| PA (1) | PA8775101A1 (es) |
| PE (1) | PE20081899A1 (es) |
| RU (1) | RU2009140313A (es) |
| SG (1) | SG182985A1 (es) |
| TW (1) | TW200904470A (es) |
| UY (1) | UY30994A1 (es) |
| WO (1) | WO2008123999A2 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5389442B2 (ja) | 2005-09-29 | 2014-01-15 | メディミューン，エルエルシー | 膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用 |
| PT2853545T (pt) * | 2008-09-17 | 2016-08-26 | Xencor Inc | Anticorpo específico para ige |
| PE20110891A1 (es) | 2008-12-09 | 2011-12-23 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
| KR20110139292A (ko) * | 2009-04-20 | 2011-12-28 | 화이자 인코포레이티드 | 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법 |
| US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
| EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US10017762B2 (en) * | 2010-11-24 | 2018-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for treating or preventing lupus |
| ES2666550T3 (es) | 2011-04-19 | 2018-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos |
| AU2013200903B2 (en) * | 2012-02-08 | 2015-05-14 | Mcure Biosciences Inc. | CDIM binding proteins and uses thereof |
| WO2013119419A1 (en) * | 2012-02-08 | 2013-08-15 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| EP3041863A4 (en) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| EP3143404B1 (en) | 2014-05-16 | 2018-08-29 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
| JP6519913B2 (ja) * | 2015-02-05 | 2019-05-29 | 国立大学法人名古屋大学 | ＩｇＥ結合性エピトープペプチドの利用 |
| WO2016164920A1 (en) | 2015-04-09 | 2016-10-13 | Cornell University | Gene therapy to prevent reactions to allergens |
| WO2016191246A2 (en) * | 2015-05-22 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for a prame peptide |
| GB201610198D0 (en) * | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| CN107686521B (zh) * | 2016-08-04 | 2021-04-06 | 越海百奥药业(绍兴)有限公司 | 一种人源化抗IgE单克隆抗体 |
| WO2018089335A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
| JP7128191B2 (ja) * | 2017-01-06 | 2022-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 治療抗ＩｇＥ抗体並びにその方法及び組成物 |
| US12503700B2 (en) | 2017-03-14 | 2025-12-23 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| WO2019183437A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for antibody to high affinity receptor for ige |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| CN114450593A (zh) | 2019-09-26 | 2022-05-06 | 美国安进公司 | 产生抗体组合物的方法 |
| KR20220091567A (ko) | 2019-11-01 | 2022-06-30 | 마젠타 테라퓨틱스 인코포레이티드 | 항-cd45 항체 및 이의 컨쥬게이트 |
| CN113372450A (zh) * | 2020-03-10 | 2021-09-10 | 北京万华生物工程有限公司 | IgE嵌合性双特异性抗体制备及应用 |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| CA3185718A1 (en) * | 2020-06-15 | 2021-12-23 | Novartis Ag | Treatment of food allergy using anti-ige antibodies |
| JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
| KR102545843B1 (ko) * | 2021-02-24 | 2023-06-20 | 주식회사 세바바이오텍 | 알러지, 아토피 및 가려움 개선용 기능성 소재의 스크리닝 방법 |
| US12467094B2 (en) | 2021-03-11 | 2025-11-11 | IgGenix, Inc. | Methods and systems for predicting allergic response |
| EP4352094A1 (en) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| US20250076309A1 (en) | 2021-10-05 | 2025-03-06 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| CN114504644B (zh) * | 2021-12-24 | 2024-02-13 | 北京大学第一医院 | 抗IgE抗体在用于治疗腺样体肥大中的应用 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0463151T3 (da) * | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) * | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| WO1992021031A1 (en) * | 1991-05-10 | 1992-11-26 | Alain De Weck | PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US6699472B2 (en) * | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0651819A1 (en) * | 1992-03-20 | 1995-05-10 | Immunet | Methods for human monoclonal antibody production |
| EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| CA2218489A1 (en) * | 1995-04-21 | 1996-10-24 | Aya Jakobovits | Generation of large genomic dna deletions |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5714352A (en) * | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| KR20010034554A (ko) | 1998-03-03 | 2001-04-25 | 레이몬드, 엠. 위티 | 치료제로서의 ｃｄ147 결합 분자 |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| AU778551B2 (en) * | 2000-01-14 | 2004-12-09 | Daiichi Pharmaceutical Co., Ltd. | Novel peptide and screening method by using the same |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20050169909A1 (en) * | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
| CN101517068B (zh) * | 2005-09-07 | 2017-02-08 | 安进弗里蒙特公司 | 活化素受体样激酶‑1的人单克隆抗体 |
-
2008
- 2008-04-01 TW TW097111898A patent/TW200904470A/zh unknown
- 2008-04-01 UY UY30994A patent/UY30994A1/es unknown
- 2008-04-01 AR ARP080101376A patent/AR065921A1/es not_active Application Discontinuation
- 2008-04-01 PE PE2008000595A patent/PE20081899A1/es not_active Application Discontinuation
- 2008-04-01 CA CA002682927A patent/CA2682927A1/en not_active Abandoned
- 2008-04-01 PA PA20088775101A patent/PA8775101A1/es unknown
- 2008-04-01 DO DO2008000018A patent/DOP2008000018A/es unknown
- 2008-04-01 AU AU2008236765A patent/AU2008236765A1/en not_active Abandoned
- 2008-04-01 WO PCT/US2008/004286 patent/WO2008123999A2/en not_active Ceased
- 2008-04-01 CN CN200880010487A patent/CN101808661A/zh active Pending
- 2008-04-01 KR KR1020097022898A patent/KR20100018499A/ko not_active Withdrawn
- 2008-04-01 SG SG2012048765A patent/SG182985A1/en unknown
- 2008-04-01 JP JP2010502126A patent/JP2010532158A/ja not_active Withdrawn
- 2008-04-01 EP EP08742484A patent/EP2142214A4/en not_active Withdrawn
- 2008-04-01 BR BRPI0809677-5A2A patent/BRPI0809677A2/pt not_active IP Right Cessation
- 2008-04-01 US US12/080,419 patent/US7867494B2/en not_active Expired - Fee Related
- 2008-04-01 GT GT200800034A patent/GT200800034A/es unknown
- 2008-04-01 MX MX2009010765A patent/MX2009010765A/es not_active Application Discontinuation
- 2008-04-01 RU RU2009140313/15A patent/RU2009140313A/ru not_active Application Discontinuation
- 2008-04-01 CL CL2008000935A patent/CL2008000935A1/es unknown
-
2009
- 2009-09-24 IL IL201156A patent/IL201156A0/en unknown
-
2010
- 2010-11-24 US US12/954,196 patent/US20110064726A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PA8775101A1 (es) | 2008-11-19 |
| US7867494B2 (en) | 2011-01-11 |
| CL2008000935A1 (es) | 2008-11-07 |
| SG182985A1 (en) | 2012-08-30 |
| KR20100018499A (ko) | 2010-02-17 |
| EP2142214A4 (en) | 2012-03-21 |
| WO2008123999A2 (en) | 2008-10-16 |
| US20110064726A1 (en) | 2011-03-17 |
| BRPI0809677A2 (pt) | 2014-10-07 |
| EP2142214A2 (en) | 2010-01-13 |
| PE20081899A1 (es) | 2009-01-26 |
| JP2010532158A (ja) | 2010-10-07 |
| AU2008236765A1 (en) | 2008-10-16 |
| US20090117124A1 (en) | 2009-05-07 |
| UY30994A1 (es) | 2008-11-28 |
| WO2008123999A9 (en) | 2009-12-10 |
| GT200800034A (es) | 2010-03-16 |
| WO2008123999A3 (en) | 2010-06-24 |
| MX2009010765A (es) | 2009-10-26 |
| IL201156A0 (en) | 2010-05-17 |
| DOP2008000018A (es) | 2008-10-15 |
| CN101808661A (zh) | 2010-08-18 |
| TW200904470A (en) | 2009-02-01 |
| RU2009140313A (ru) | 2011-05-10 |
| CA2682927A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065921A1 (es) | Anticuerpos anti-ige | |
| CN104667271B (zh) | 能与人B淋巴细胞上的mIgE结合的抗CεmX抗体 | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 | |
| MY153893A (en) | Antibodies against human il17 and uses thereof | |
| BRPI0617485B8 (pt) | anticorpo anti-il-13 humano isolado, composição farmacêutica e uso do referido anticorpo | |
| CL2008002565A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente al dominio extracelular de cxcr5/receptor de linfoma de burkitt (blr1)/cd185/mdr15/mgc117347 humano; molécula de ácido nucleico aislada que lo codifica; vector que comprende a dicha molécula de ácido nucleico; célula huésped aislada que comprende a dicho vector; uso médico de dicho anticuerpo; y composición farmacéutica que lo comprende. | |
| AR064109A1 (es) | Anticuerpos humanos que se enlazan al cd22 y sus usos | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| BRPI0607486B8 (pt) | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| UA116614C2 (uk) | Антитіло до фактора d і його застосування | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| BRPI0513078B8 (pt) | anticorpo igg que se liga a il-17 humana e composição líquida | |
| AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
| ATE492561T1 (de) | Verbesserte protofibrilselektive antikörper und deren verwendung | |
| CL2013003244A1 (es) | Anticuerpo monoclonal que se une especificamente a la proteina rgm; acido nucleico aislado que lo codifica; vector; celula huesped, metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar enfermedades neurologicas (div. sol.n°459-09) | |
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| BRPI0611414B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos | |
| BRPI0821168B8 (pt) | anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma | |
| ECSP099645A (es) | Anticuerpos anti ige apoptóticos | |
| DOP2010000170A (es) | Proteinas de union a antigenos | |
| BR112013007314A2 (pt) | anticorpos anti-cd48 e seus usos | |
| WO2010012004A3 (en) | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence | |
| JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل | |
| PE20060560A1 (es) | Anticuerpos de interleucina-4 humana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |